Three drugs may be better than one for certain patients with advanced colorectal cancer

Patients with a form of advanced colorectal cancer that is driven by a mutated version of the BRAF gene have limited treatment options available. However, results, reported at the 26th EORTC-NCI-AACR Symposium, from a multi-center clinical trial suggest that the cancer may respond to a combination of three targeted drugs: encorafenib, cetuximab and alpelisib. —> Read More Here


Leave a Reply

Your email address will not be published. Required fields are marked *